PUBLISHER: DelveInsight | PRODUCT CODE: 2168694
PUBLISHER: DelveInsight | PRODUCT CODE: 2168694
Chronic Pain Market size and forecast
DelveInsight's "Chronic Pain - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of chronic pain, historical and forecasted epidemiology, as well as the chronic pain market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The chronic pain market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, chronic pain patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in chronic pain and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.
North America: The United States
Europe: Germany, France, Italy, Spain and the United Kingdom
Asia-Pacific: Japan
Chronic Pain Overview and Diagnosis
Chronic pain is a complex and persistent condition defined as pain lasting beyond the normal healing period, typically for more than 3-6 months. It affects a substantial proportion of the adult population and is associated with significant physical, psychological, and socioeconomic burden. Chronic pain may arise from tissue injury, disease, nerve damage, or altered pain processing, and is frequently accompanied by comorbid conditions such as depression and anxiety, which further impair quality of life and functional capacity. The condition is also associated with increased healthcare utilization, reduced productivity, opioid misuse, and elevated mortality risk.
The diagnosis of chronic pain requires a comprehensive and multidisciplinary evaluation aimed at identifying the underlying cause, determining the predominant pain mechanism, and assessing the impact of pain on physical, psychological, and social functioning. Because chronic pain may arise from musculoskeletal, neuropathic, inflammatory, visceral, or nociplastic mechanisms, diagnosis is based on a combination of clinical assessment and targeted diagnostic investigations. A thorough physical examination helps identify structural, neurological, or inflammatory abnormalities that may contribute to chronic pain. Examination typically includes assessment of posture, gait, joint range of motion, muscle strength, tenderness, swelling, sensory changes, reflexes, and signs of nerve compression or musculoskeletal dysfunction.
Current Chronic Pain Treatment Landscape
The management of chronic pain requires a multimodal and individualized approach that addresses pain intensity, functional impairment, psychological comorbidities, and the underlying pain mechanism. Because chronic pain may be nociceptive, neuropathic, inflammatory, visceral, or nociplastic in origin, treatment is typically tailored to the predominant mechanism and the patient's clinical profile. Current management combines pharmacological therapies, non-pharmacological interventions, interventional procedures, and multidisciplinary rehabilitation, with the goal of improving function and quality of life rather than eliminating pain completely.
Non-opioid analgesics such as acetaminophen and NSAIDs are considered first-line therapies for many chronic musculoskeletal conditions, while opioids are generally reserved for severe, persistent, or refractory pain when non-opioid therapies have failed or are contraindicated. Other commonly used pharmacological treatments include anticonvulsants and antidepressants, particularly for neuropathic, nociplastic, fibromyalgia, and chronic musculoskeletal pain. Topical therapies such as lidocaine, capsaicin, and topical NSAIDs may be used for localized neuropathic or musculoskeletal pain. Treatment is generally individualized and requires ongoing reassessment of pain relief, physical function, mental health, medication-related harms, and patient-centered goals.
Chronic Pain Unmet Needs
The section "unmet needs of chronic pain" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.
Key Findings from Chronic Pain Epidemiological Analysis and Forecast
Chronic Pain Drug Analysis & Competitive Landscape
The chronic pain drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the chronic pain treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the chronic pain therapeutics market.
Approved Therapies Chronic Pain
Atogepant (AQUIPTA/QULIPTA): AbbVie
Atogepant is approved for migraine prophylaxis in more than 60 countries and is marketed as AQUIPTA in the EU and QULIPTA in the US, Canada, Israel, and Puerto Rico. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide, which is thought to play a causal role in migraine.
Chronic Pain Pipeline Analysis
SL1002: Saol Therapeutics
SL-1002 is a novel injectable chemoneurolytic agent being developed specifically for chronic knee pain associated with osteoarthritis. It is designed as a single-treatment approach for persistent osteoarthritis-related knee pain, with Phase II evaluation completed and a Phase III study currently underway in patients with mild-to-moderate knee osteoarthritis.
Chronic Pain Key Players, Market Leaders and Emerging Companies
Chronic Pain Drug Updates
The market outlook for chronic pain remains positive, driven by a growing patient population, increasing disease awareness, improved diagnosis, and a substantial unmet need for effective long-term therapies. Current approaches primarily focus on pain relief and improving physical function through pharmacological and non-pharmacological interventions; however, many patients continue to experience persistent pain and functional limitations. A growing pipeline of novel and targeted therapies is expected to further evolve the treatment landscape, while continued research and advances in personalized and multimodal approaches may improve patient outcomes, reduce disease burden, and support market growth.
Drug Class/Insights into Leading Emerging Therapies in Chronic Pain (2026-2036 Forecast)
Novel Non-Opioid and Targeted Therapies: Emerging therapies represent an increasingly diversified approach in chronic pain, with candidates targeting chronic low back pain, osteoarthritis, migraine, fibromyalgia, and neuropathic pain through mechanism-specific, non-opioid, regenerative, and extended-release strategies. The pipeline includes biologics, monoclonal antibodies, small molecules, regenerative therapies, and extended-release formulations designed to provide sustained pain relief, improve functional outcomes, and address underlying drivers of chronic pain.
Chronic Pain Drug Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the chronic pain drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.
The emerging treatment landscape for chronic pain is expected to be shaped by therapies with varying adoption rates based on their clinical efficacy, stage of development, safety profile, and ability to address key unmet needs. Zenagamtide, Retatrutide, and SL1002 are anticipated to achieve medium uptake, supported by their promising clinical potential and potential to address unmet treatment needs, although adoption may be influenced by factors such as clinical differentiation, regulatory timelines, pricing, reimbursement, and the need for additional clinical and long-term evidence. In contrast, IncobotulinumtoxinA is expected to demonstrate medium-fast uptake, supported by its established therapeutic platform and potential role in chronic pain management, although uptake may be moderated by clinical positioning, treatment guidelines, and reimbursement considerations. Collectively, these therapies are expected to expand treatment options for chronic pain, improve disease management, and contribute to the gradual evolution of the treatment paradigm over the forecast period.
Detailed insights of emerging therapies' drug uptake is included in the report...
Market Access and Reimbursement of Therapies in Chronic Pain
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.
NOTE: Further Details are provided in the final report.
Chronic Pain Therapies Price Scenario & Trends
Pricing and analogue assessment of chronic pain therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.
Industry Experts and Physician Views for Chronic Pain
To keep up with chronic pain market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the chronic pain emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in chronic pain, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight's analysts connected with 30+ KOLs to gather insights at country level. Leading centers such as Harvard University and Friedrich Schiller University Jena, Brigham and Women's Hospital, Aichi Medical University, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.
Their opinion helps understand and validate current and emerging chronic pain therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in chronic pain.
Qualitative Analysis: SWOT and Attribute Analysis
We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.
In the SWOT analysis of chronic pain, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provide attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
The team analyzed promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Insights